---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060513"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:46:57.472442+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024

## Summary
- Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.
- Non-GAAP Adjusted EBITDA turned positive at $11K ($0.001 per share) vs negative $5.3M prior year.
- R&D expenses rose to $7.9M from $2.0M due to $4M FDA filing fee and $3M DRL milestone for DFD-29.
- SG&A cut 37% to $8.4M; Qbrexza and Accutane each grew >20% YoY.
- FDA accepted DFD-29 NDA for rosacea; PDUFA target action date November 4, 2024.

## SEC filing metadata
- accession: 0001104659-24-060513
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/0001104659-24-060513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/tm2414271d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060513
- JSON: https://secwatch.observer/filing/0001104659-24-060513.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060513.txt

## Key facts
- Earnings Releases
  Journey Medical Corp reported first quarter ended March 31, 2024 results: revenue Total net product revenues were $13.0 million, net income Net loss was $10.4 million, EPS $(0.53) per share basic and diluted.
  - Period: first quarter ended March 31, 2024
  - Revenue: Total net product revenues were $13.0 million
  - Net income: Net loss was $10.4 million
  - EPS: $(0.53) per share basic and diluted
  - Result: reported results
  source text: New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465924060513/0001104659-24-060513-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.